Lannett Company Inc. today announced that it and certain selling stockholders intend to offer shares of the Company’s common stock in an underwritten public offering.
The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Roth Capital Partners LLC and Canaccord Genuity Inc. are acting as joint book-running managers and Oppenheimer & Co. Inc. is acting as lead manager for the proposed offering.
The Company intends to use the net proceeds it receives from the proposed offering for general corporate purposes including without limitation research and development general and administrative manufacturing and marketing expenses and for potential acquisitions of companies products ANDAs technologies and assets that complement its business. The Company will not receive any proceeds from the sale of any shares by any selling stockholders.
The shares described above are being offered pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission (SEC). The final terms of the offering will be disclosed in a final prospectus supplement filed with the SEC.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein nor shall there be any sale of these securities in any state or jurisdiction in which such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Lannett Company Inc.:
Lannett Company founded in 1942 develops manufactures packages markets and distributes generic pharmaceutical products for a wide range of medical indications.
